← Back to Search

Gene Therapy

Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial) (EXACT Trial)

Phase 1 & 2
Waitlist Available
Research Sponsored by XyloCor Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing XC001, a treatment that helps grow new blood vessels in the heart, in patients with severe angina who have no other treatment options. It works by using a gene to produce a protein that promotes new blood vessel growth. Gene therapy for cardiovascular diseases, including the use of vascular endothelial growth factor (VEGF) to promote new blood vessel growth, has been explored for many years.

Eligible Conditions
  • Refractory Angina
  • Coronary Artery Disease
  • Heart Disease
  • Cardiovascular Disease
  • Single Ventricle Heart Disease
  • Ischemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Primary Endpoint (adverse events)
Secondary study objectives
Secondary Endpoint (Angina episodes)
Secondary Endpoint (Canadian Cardiovascular Society angina class)
Secondary Endpoint (Exercise tolerance test)
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: AdVEGFXC1 at 4x10^10 vpExperimental Treatment1 Intervention
Group II: AdVEGFXC1 at 1x10^9 vpExperimental Treatment1 Intervention
Group III: AdVEGFXC1 at 1x10^11 vpExperimental Treatment1 Intervention
Group IV: AdVEGFXC1 at 1x10^10 vpExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AdVEGFXC1
2020
Completed Phase 2
~50

Find a Location

Who is running the clinical trial?

XyloCor Therapeutics, Inc.Lead Sponsor
~7 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top